D-0659-2024 Class III Ongoing
FDA drug recall D-0659-2024 was initiated by Rubicon Research Private Limited on August 24, 2024 and is designated Class III. Reason for recall: Discoloration The recall status is ongoing. Affected quantity: 3,984 bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- September 25, 2024
- Initiation Date
- August 24, 2024
- Termination Date
- N/A
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 3,984 bottles
Product Description
AcetaZOLAMIDE Tablets, USP, 125 mg, 100 count bottled, Rx Only, Distributed by: Advagen Pharma Limited, Plainsboro, NJ, Manufactured by Rubicon Research Private Limited, Thane, India NDC 72888-047-01
Reason for Recall
Discoloration
Distribution Pattern
Nationwide in the US
Code Information
Lot # 30575HF1, exp. date, Nov 2026 NDC# 72888-047-01